Ac225-DOTA-M5A / City of Hope, National Cancer Institute - Bethesda - LARVOL DELTA

Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Mar 2024 ➔ Aug 2025 | Trial primary completion date: Mar 2024 ➔ Aug 2025

Metastases • Trial completion date • Trial primary completion date • Oncology

Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Positive Advanced Colorectal Cancer (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: City of Hope Medical Center | Not yet recruiting ➔ Recruiting

Enrollment open • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor